^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lucentis (ranibizumab)

    i
    Other names: RG3645, RG-3645, RG 3645, rhuFabV2
    Associations

    News

    Trials
    Company:
    Novartis, Roche
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    23d
    A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD (clinicaltrials.gov)
    P3, N=388, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Aug 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Lucentis (ranibizumab)
    29d
    Pagoda: This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (clinicaltrials.gov)
    P3, N=634, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Feb 2024 --> Feb 2025
    Trial completion date
    |
    Lucentis (ranibizumab)
    1m
    Molecular Basis of Angiogenesis and its Application. (PubMed, Keio J Med)
    Ranibizumab not only maintained but also improved visual acuity and has been approved worldwide for the treatment of wet AMD and other neovascular disorders. Other VEGF inhibitors, including bevacizumab and aflibercept, have also resulted in significant clinical benefits. Today anti-VEGF drugs represent the most effective therapy for intraocular neovascularization. Current research addresses the need to reduce the frequency of intravitreal injections as well the identification of additional pro-angiogenic pathways that could result in improving therapeutic outcomes.
    Journal
    |
    KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1)
    |
    Avastin (bevacizumab) • Lucentis (ranibizumab)
    2ms
    Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD (clinicaltrials.gov)
    P1, N=24, Completed, Shanghai Biomabs Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    2ms
    Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov)
    P4, N=0, Withdrawn, Wake Forest University Health Sciences | N=150 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Visudyne (verteporfin) • Lucentis (ranibizumab)
    2ms
    ShORe: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=990, Recruiting, Opthea Limited | Trial completion date: Jul 2025 --> Jul 2026
    Trial completion date • Combination therapy
    |
    Lucentis (ranibizumab)
    2ms
    ShORe: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=990, Recruiting, Opthea Limited | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Lucentis (ranibizumab)
    2ms
    A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=70, Recruiting, Incepta Pharmaceuticals Ltd
    New P3 trial
    |
    Lucentis (ranibizumab)
    2ms
    ATMOSPHERE: Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (clinicaltrials.gov)
    P2/3, N=300, Recruiting, AbbVie | Phase classification: P2b --> P2/3
    Phase classification • Gene therapy
    |
    Lucentis (ranibizumab)
    2ms
    POYANG: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov)
    P3, N=280, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lucentis (ranibizumab)
    3ms
    FAR-WEST: Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Nantes University Hospital
    New trial
    |
    Lucentis (ranibizumab)
    3ms
    Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab (clinicaltrials.gov)
    P=N/A, N=13, Completed, Rigshospitalet, Denmark
    New trial
    |
    Lucentis (ranibizumab)
    3ms
    Compound Danshen dripping pills prevent early diabetic retinopathy: roles of vascular protection and neuroprotection. (PubMed, Front Pharmacol)
    The drugs currently used for treatment, such as ranibizumab, mainly focus on the middle and late periods of DR, and thus do not meet the clinical need...Moreover, CDDP reduced the expression levels of inflammatory factors in both the retina and serum. These findings strongly suggest that CDDP prevents early DR through vascular and neuroprotection.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • ICAM1 (Intercellular adhesion molecule 1) • CCL2 (Chemokine (C-C motif) ligand 2)
    |
    Lucentis (ranibizumab)
    4ms
    A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov)
    P3, N=400, Recruiting, Outlook Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lucentis (ranibizumab)
    4ms
    Belvedere: A Study Assessing Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (clinicaltrials.gov)
    P4, N=185, Recruiting, Genentech, Inc. | N=58 --> 185 | Trial completion date: Jan 2024 --> Apr 2027 | Trial primary completion date: Jan 2024 --> Apr 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Lucentis (ranibizumab)
    4ms
    A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Outlook Therapeutics, Inc.
    New P3 trial
    |
    Lucentis (ranibizumab)
    5ms
    A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO (clinicaltrials.gov)
    P2, N=34, Completed, Samsung Bioepis Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    5ms
    A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, Samsung Bioepis Co., Ltd.
    New P2 trial
    |
    Lucentis (ranibizumab)
    5ms
    POYANG: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov)
    P3, N=280, Not yet recruiting, Hoffmann-La Roche
    New P3 trial
    |
    Lucentis (ranibizumab)
    5ms
    Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov)
    P4, N=150, Suspended, Wake Forest University Health Sciences | Recruiting --> Suspended
    Trial suspension
    |
    Visudyne (verteporfin) • Lucentis (ranibizumab)
    5ms
    A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema (clinicaltrials.gov)
    P2, N=394, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lucentis (ranibizumab)
    5ms
    Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=442, Recruiting, Laboratorios Sophia S.A de C.V. | Trial completion date: Dec 2023 --> Aug 2025 | Trial primary completion date: Dec 2023 --> Aug 2025
    Trial completion date • Trial primary completion date • Head-to-Head
    |
    Avastin (bevacizumab) • Lucentis (ranibizumab)
    5ms
    ShORe: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=990, Recruiting, Opthea Limited | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date
    |
    Lucentis (ranibizumab)
    6ms
    BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P1, N=251, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: May 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Lucentis (ranibizumab)
    over1year
    Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov)
    P2, N=120, Recruiting, Carmen Clapp | Trial completion date: Dec 2022 --> Feb 2024 | Trial primary completion date: Sep 2022 --> Nov 2023
    Trial completion date • Trial primary completion date
    |
    PRL (Prolactin)
    |
    Lucentis (ranibizumab)
    almost2years
    AAVCAGsCD59 for the Treatment of Wet AMD (clinicaltrials.gov)
    P1 | N=25 | Completed | Sponsor: Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Avastin (bevacizumab) • Lucentis (ranibizumab)
    2years
    Diagrid: A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P3 | N=560 | Not yet recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Mar 2025 --> Sep 2025
    Trial completion date
    |
    Lucentis (ranibizumab)
    3years
    Identification of potential candidate genes for lip and oral cavity cancer using network analysis. (PubMed, Genomics Inform)
    VEGFA, IL6, MAPK3, INS, TNF, MAPK8, MMP9, CXCL8, EGF, and PTGS2 were recognized as network hub genes using the maximum clique centrality algorithm available in cytoHubba, and nine potential drug candidates (ranibizumab, siltuximab, sulindac, pomalidomide, dexrazoxane, endostatin, pamidronic acid, cetuximab, and apricoxib) for lip and oral cavity cancer were identified from the DGIdb database. Gene enrichment analysis was also performed to identify the gene ontology categorization of cellular components, biological processes, molecular functions, and biological pathways. The genes identified in this study could furnish a new understanding of the underlying molecular mechanisms of carcinogenesis and provide more reliable biomarkers for early diagnosis, prognostication, and treatment of lip and oral cavity cancer.
    Journal
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • MMP9 (Matrix metallopeptidase 9) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK8 (Mitogen-activated protein kinase 8)
    |
    Erbitux (cetuximab) • pomalidomide • Sylvant (siltuximab) • Capoxigem (apricoxib) • Lucentis (ranibizumab) • dexrazoxane